Galectin Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galectin Therapeutics Inc.
The 10 US Biosimilar Launches That Could Drive Big Savings By 2027
Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.
Former Seagen CEO Siegall Takes Helm At New Biotech Morphimmune
Siegall is moving on after an unhappy exit from Seagen with a new role at another company with a novel targeted oncology platform.
Who’s Hired? Sandoz Names Post-Spinoff Chair
Sandoz has announced the appointment of a chairman-designate ahead of its planned separation from parent company Novartis this year. Meanwhile, Canadian industry association the CGPA has also named a new chair and vice-chair, while Formycon has appointed a new CFO.
Eylea Race Continues To Heat Up With Formycon Unveiling Early Positive Data
Weeks after Coherus BioSciences put pen to paper on a deal to bring in Formycon’s FYB203 proposed biosimilar to Eylea (aflibercept), the candidate has shown positive efficacy and safety data, according to preliminary Phase III trial results.
- Drug Delivery
- Other Names / Subsidiaries
- Galectin Sciences, LLC
- Pro-Pharmaceuticals Inc.
- Galectin Therapeutics Security Corp.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.